Featured Research

from universities, journals, and other organizations

Fatal fungal infections resist newest class of drugs

Date:
September 6, 2011
Source:
Society for General Microbiology
Summary:
Fungi that cause severe infections in those with compromised immune systems are resisting the action of the latest group of antifungal drugs. Uncovering their strategies for doing this will lead to more effective treatments, says a scientist.

Fungi that cause severe infections in those with compromised immune systems are resisting the action of the latest group of antifungal drugs. Uncovering their strategies for doing this will lead to more effective treatments, says a scientist speaking at the Society for General Microbiology's Autumn Conference at the University of York.

Related Articles


Candida albicans is the most common hospital-acquired fungal infection and can cause illness by sticking to and colonizing plastic surfaces implanted in the body such as catheters, cardiac devices or prosthetic joints. From there the fungus can spread through the bloodstream to the major organs. While normally harmless to healthy individuals, C. albicans can cause fatal infections in immunocompromised people such as those suffering from cancer, trauma and organ transplantation.

Fungi such as C. albicans are covered in a sugar-rich outer layer (cell wall) that protects the fungus from the environment. The newest class of antifungal drugs, the echinocandins, targets the enzyme that makes one of the two key sugar polymers found in the cell wall, called beta-glucan. Scientists at the University of Aberdeen are investigating how C. albicans responds to echinocandins and have shown how the fungus is able to change the structure of its cell wall to render the drug ineffective.

Dr Carol Munro who is leading the research along with Professor Neil Gow explained, "If levels of drug are used that do not kill the fungus straight away, C. albicans responds by producing an excess of the other key cell wall sugar polymer, called chitin. Fungal cells displaying higher levels of chitin can survive treatment with echinocandins, allowing infection to progress."

Echinocandins are given by IV injection and have a relatively broad spectrum of activity against most Candida species. The increasing number of reports of sporadic breakthrough infections in patients receiving echinocandin therapy is worrying, explained Dr Munro. "Echinocandins are used to treat Candida infections that may already be resistant to the azole group of antifungals. Healthcare specialists must be made aware of the potential problems and should keep up to date with the results of global surveillance programmes reported in the specialist literature."

The group's work will help improve treatment options for patients who experience antifungal failure. "Understanding the mechanisms of drug resistance will help us determine when it is appropriate to switch to a different drug regime. Our work so far suggests that the use of drugs that inhibit the production of chitin (if they were available), in combination with echinocandins, would improve treatment effectiveness for Candida infections," said Dr Munro. This work therefore, also impacts on the development of much needed novel antifungal therapies.


Story Source:

The above story is based on materials provided by Society for General Microbiology. Note: Materials may be edited for content and length.


Cite This Page:

Society for General Microbiology. "Fatal fungal infections resist newest class of drugs." ScienceDaily. ScienceDaily, 6 September 2011. <www.sciencedaily.com/releases/2011/09/110906191631.htm>.
Society for General Microbiology. (2011, September 6). Fatal fungal infections resist newest class of drugs. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2011/09/110906191631.htm
Society for General Microbiology. "Fatal fungal infections resist newest class of drugs." ScienceDaily. www.sciencedaily.com/releases/2011/09/110906191631.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins